MITIDE

This brand name is authorized in Nigeria.

Active ingredients

The drug MITIDE contains one active pharmaceutical ingredient (API):

1	Bicalutamide UNII A0Z3NAU9DP - BICALUTAMIDE
	Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition.
	Read more about Bicalutamide

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-3936	Tablet	Mitide Tablets_ TAB 50 mg 1 x 30's (in blisters or HDPE bottle)	Film-coated Tablets. Yellow coloured, round-shaped biconvex tablet, both sides plain. MITIDE TABLETS BICALUTAMIDE TABLETS USP 50MG BICALUTAMIDE USP 50MG Q.S. B4-3936 Drugs Imported Products 1X30 Prescription Only Medicine (POM) 03/12/2023 MANOLA PHARMACEUTICALS LTD, BLOCK 89A, OBA KAYODE AKNYEMI WAY, AMUWO ODOFIN LAGOS LAGOS LAGOS 8103078742 regulatorymanola@gmail.com NAPROD LIFE SCIENCES PVT. LTD, G-17/1, M.I.D.C., BOISAR THANE, INDIA, India	28/08/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02BB03	Bicalutamide	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BB Anti-androgens
Discover more medicines within L02BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-3936